Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women
University of Delaware · with National Institute on Aging (NIA) · NCT06745466
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 40–55 · Women only
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 4
- Target enrollment
- 30
- US sites recruiting
- 1
- Study start
- November 15, 2024
- Record last updated
- July 2, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this study is to identify the impact of estradiol (E2) on the associations between (a) responsivity to daily stress or (b) sleep variability with vascular function in midlife premenopausal women.
Being studied: ganirelix acetate
Conditions: Estrogen; Premenopause
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Female
- Age 40-55
- Premenopausal
Exclusion Criteria
- Pregnancy (including a positive urine pregnancy test), planning to become pregnant, or breast-feeding
- Peri- or post-menopausal
- Unstable or diagnosed chronic clinical disease, including cardiovascular, metabolic, renal, hepatic, autonomic, autoimmune, or dermatological disease
- Current or lifetime major psychiatric illness (e.g., major depressive disorder, bipolar disorder, schizophrenia, eating disorders)
- History of hysterectomy (complete or partial), polycystic ovary syndrome, endometrial hyperplasia, irregular menstrual cycles, or endometrial ablation
- Suspected potential presence of obstructive sleep apnea (STOP-Bang score >3) or insomnia (Insomnia Severity Index score >15)
- Current or recent (within 8 wks) use of medications that could conceivably alter cardiovascular function or sleep health
- Changes or alterations in medication status (starting a new, additional, or different medication or changing the dose of a current medication)
- Body mass index >35 kg/m2
- Tobacco or nicotine use, including vaping and electronic cigarettes
- Working night-time or rotating shift work within the previous 3 months
- Trans-meridian travel during study enrollment (inclusive of the entire duration of enrollment and the period between testing cycles)
- Known allergies to pharmacological agents/drugs
- Current use of long-acting reversible contraception (LARC; e.g., IUDs, birth control implants)
- Known latex allergy
Recruiting US locations
University of Delaware
Newark, DE 19713
Site contact: Jody Greaney, PhD · 302-831-2193 · jgreaney@udel.edu
Study contacts (from the official record)
- Jody Greaney, PhD · 302-831-2193 · jgreaney@udel.edu
- Virginia Nuckols, PhD · gnuckols@udel.edu
Similar studies in Delaware
All sleep studies in Delaware →- RecruitingPhase 3
A Study of Pitolisant in Patients With Prader-Willi Syndrome
Harmony Biosciences Management, Inc.
- Location
- Wilmington, DE + 18 other US sites
- Eligibility basics
- Ages 6+